STAVUDINE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

InChI

InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N

InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00649
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf

Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Stavudine is used for the treatment of human immunovirus (HIV) infections. Stavudine is sold under the brand name Zerit among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus 1 34 Target ID: CHEMBL378 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Inhibitor 8504		1.9 µM [IC50]
Human immunodeficiency virus type 1 reverse transcriptase 70 Target ID: CHEMBL247 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Inhibitor 8504		0.0083 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 156 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Primary		Approved 8583	Zerit Approved Use ZERIT (stavudine), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection Launch Date 1994

C_max

Value	Dose	Co-administered	Analyte	Population
228 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
536 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1966 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2568 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/	unhealthy, 36.5 Health Status: unhealthy Age Group: 36.5 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/	Other AEs: Abdominal pain, Asthenia... Other AEs: Abdominal pain (19%) Asthenia (18%) Headache (25%) Diarrhea (34%) Dyspepsia (12%) Nausea (24%) Vomiting (12%) Lipodystrophy (6%) Arthralgia (6%) Myalgia (4%) Abnormal dreams (19%) Depressive disorders (13%) Dizziness (26%) Insomnia (22%) Neuropathy (13%) Paresthesia (12%) Cough increased (9%) Rhinitis (11%) Rash (35%) Skin discoloration (<1%) Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Headache, Diarrhea... Other AEs: Headache (54 patients) Diarrhea (50 patients) Neuropathy peripheral (52 patients) Rash (40 patients) Nausea and vomiting (39 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (43 patients) Diarrhea (34 patients) Headache (25 patients) Rash (18 patients) Vomiting (18 patients) Neuropathy peripheral (8 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (53 patients) Diarrhea (45 patients) Headache (46 patients) Rash (30 patients) Vomiting (30 patients) Neuropathy peripheral (21 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 1057 CYP2B6 926 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 BSEP 550 MRP2 499 MRP3 246 MRP4 290	CYP1A2 1197 CYP2C19 1119 BCRP 697 P-gp 2052	P-gp 301

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	unlikely
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	weak
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/18310046/	weak

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17202245/	yes
P-gp 2052	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0024320510004005	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63581	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63581
ChemicalBook	CB4450928	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4450928
eMolecules	536927	https://www.emolecules.com/cgi-bin/more?vid=536927
eMolecules	739264	https://www.emolecules.com/cgi-bin/more?vid=739264
MolPort	MolPort-002-507-283	https://www.molport.com/shop/molecule-link/MolPort-002-507-283
ZINC	ZINC000000137884	http://zinc15.docking.org/substances/ZINC000000137884

PubMed

Title	Date	PubMed
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.	1999 Mar	10051538
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.	1999 May 6	10229630
cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.	1999 May 6	10229629
Didanosine-induced hepatitis.	2000 Aug	10950090
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.	2000 Aug	10898683
Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases.	2000 Aug 1	10906833
Activities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages.	2000 Jan	10602742
Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy.	2000 Jun 16	10894300
Sudden unexpected death as a consequence of indinavir-induced nephropathy. A case report.	2000 Sep	11110045
Synthesis and antiviral activity of C-5 substituted beta-D- and beta-L-D4T analogues.	2000 Sep	11092314
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.	2000 Sep 18	10999490
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study.	2000 Sep 29	11061656
Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV.	2001	11480491
Macrocytosis in patients on stavudine.	2001	11303821
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.	2001 Apr	11306154
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1.	2001 Apr	11306153
Gynecomastia associated with highly active antiretroviral therapy.	2001 Apr	11302408
Treatment of hyperlipidemia in HIV-infected patients.	2001 Apr 1	11296612
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.	2001 Apr 13	11371696
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.	2001 Apr 13	11371686
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.	2001 Apr 13	11355843
The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.	2001 Apr 27	11134027
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.	2001 Aug 1	11468426
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.	2001 Aug 15	11471110
Bristol-Myers warns of AIDS drugs' use.	2001 Feb	11279879
Genetic risks of antiviral nucleoside analogues--a survey.	2001 Feb	11248359
Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy.	2001 Feb 16	11273225
Gene mutations identified.	2001 Jan	11265651
Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.	2001 Jan 26	11216932
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.	2001 Jan-Feb	11488127
New developments in anti-HIV chemotherapy.	2001 Jan-Feb	11347962
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.	2001 Jul	11486172
Predictors of protease inhibitor-associated adverse events.	2001 Jul	11478584
Stavudine versus zidovudine and the development of lipodystrophy.	2001 Jul 1	11464142
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.	2001 Jul 27	11504959
Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis.	2001 Jul-Aug	11485138
Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.	2001 Jun	11491422
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.	2001 Jun	11368826
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.	2001 Jun 29	11442229
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.	2001 Jun 29	11319228
Peripheral neuropathy and antiretroviral drugs.	2001 Mar	11293802
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.	2001 Mar 30	11316999
An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase.	2001 May 1	11319828
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.	2001 May 5	11356442
Warning for pregnant women on HIV therapy.	2001 May-Jun	11458554
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.	2001 Sep	11448730
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.	2001 Sep 14	11454872

Patents

Sample Use Guides

In Vivo Use Guide

Adults: The recommended dose based on body weight is as follows: 40 mg twice daily for patients ≥60 kg. 30 mg twice daily for patients <60 kg.

Route of Administration: Oral

In Vitro Use Guide

The concentration of Stavudine necessary to inhibit HIV-1 replication by 50% (EC50) ranged from 0.009 to 4 uM

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:04:54 GMT 2025` Edited by `admin` on `Wed Apr 02 07:04:54 GMT 2025`
Record UNII	BO9LE4QFZF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SANILVUDINE

Preferred Name

English

STAVUDINE

Official Name

English

STAVUDINE [WHO-IP]

Common Name

English

STAVUDINE [MI]

Common Name

English

STAVUDINE [USAN]

Common Name

English

STAVUDINE (D4T) [VANDF]

Common Name

English

Stavudine [WHO-DD]

Common Name

English

ZERIT

Brand Name

English

D-4T

Code

English

STAVUDINE [USP MONOGRAPH]

Common Name

English

NSC-163661

Code

English

stavudine [INN]

Common Name

English

STAVUDINE [EP MONOGRAPH]

Common Name

English

THYMIDINE, 2',3'-DIDEHYDRO-3'-DEOXY-

Systematic Name

English

NSC-759897

Code

English

STAVUDINUM [WHO-IP LATIN]

Common Name

English

STAVUDINE [EMA EPAR]

Common Name

English

STAVUDINE [HSDB]

Common Name

English

ZIDOVUDINE IMPURITY A [WHO-IP]

Common Name

English

1-((2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE

Common Name

English

STAVUDINE [EP IMPURITY]

Common Name

English

STAVUDINE (DT4) [VANDF]

Common Name

English

STAVUDINE [ORANGE BOOK]

Common Name

English

STAVUDINE [MART.]

Common Name

English

1-(2,3-DIDEOXY-.BETA.-D-GLYCERO-PENT-2-ENOFURANOSYL)THYMINE

Common Name

English

ZIDOVUDINE IMPURITY A [EP IMPURITY]

Common Name

English

STAVUDINE [USP-RS]

Common Name

English

SANILVUDINE [JAN]

Common Name

English

D4T

Code

English

Classification Tree Code System Code

NDF-RT

N0000175462